Griffin Securities Sees More Countries Approving Intrexon's (XON) OX513A Amid Zika Pandemic
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Fibrocell Highlights Recent Pipeline Accomplishments
January 27, 2016 8:01 AM ESTPatient Dosing in Phase II Trial of azficel-T for Chronic Dysphonia Completed Preclinical Toxicology Study for FCX-007 InitiatedPositive POC Data Shows FCX-013 Reduces Dermal Thickness of Fibrotic Tissue
EXTON, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ: FCSC), an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs, today highlighted several recent accomplishments related to the continued advancement of the companys pipeline.
Recently, Fibrocell has made significant progress across our pipeline of personalized biologics, positioning the company to achieve... More
